Jonathan Bush, Athenahealth chairman, CEO & president, speaks with CNBC's Meg Tirrell at about Obamacare and the potential repeal of the law.
CNBC's Meg Tirrell talks to Illumina CEO Francis deSouza about lowering the price of genome sequencing and the opportunity it opens up for advancements in medical research.
CNBC's Meg Tirrell speaks with Alexion Pharmaceuticals interim CEO David Brennan about the recent changes in the company's leadership.
CNBC's Meg Tirrell speaks with Eli Lilly President & CEO David Ricks about President-elect Donald Trump's views on the problems of drug pricing and his potential tax policies.
CNBC's Meg Tirrell talks to BioMarin Pharmaceutical CEO Jean-Jacques Bienaime, about the outlook on the drug industry.
First Response now has a pregnancy test tied to a health app that helps users manage their stress as it monitors hormone levels. What next?
These are the states with the leading programs based on quality controls, patient safety and civil protections, according to ASA Foundation.
Demand for home medical devices is booming. Innovations keep rolling out — from smart baby monitors to infrared thermometers.
Ex Apple and Pepsi CEO wants to transform the"antiquated" health care industry
Biotech CEOs say that drug pricing needs to be balanced enough to support research and development.
Ipsita Smolinksi, Capitol Street; Dr. Ron Cohen, Acorda; and Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy,discuss rising drug prices and affordable care for patients.
Dr. Flemming Ornskov, Shire PLC CEO, discusses rare diseases and the economics behind his deal with Baxalta.
CNBC's Meg Tirrell sits down with Dr. Flemming Ornskov, Shire PLC CEO, to discuss Shire's deal with Baxalta worth $32 billion.
Bristol-Myers Squibb CEO Dr. Giovanni Caforio, provides insight to his company's position in the biotech industry, and the thinking about pricing in cancer drugs.
BioMarin CEO Jean-Jacques Bienaime, discusses drug pricing, the sentiment of investors in biotech and his expectations for the company's Duchenne muscular dystrophy drug.
Checking on the biotech industry, and the outlook for ARIAD Pharmaceuticals, with Alex Denner, Sarissa Capital Management founder and CIO.
GlaxoSmithKline CEO Sir Andrew Witty says he expects growth in his firm's three major businesses.
Regeneron CEO Len Schleifer says drug pricing needs to be balanced enough to support research and development.
Samuel Waksal, Kadmon Corporation founder, shares his thesis on pricing in the pharmaceutical industry.
This company promises to detect cancer early by performing liquid biopsies.
Insurers are uncertain over the fate of so-called cost-sharing reduction subsidies.
Uncertainty over the cost-sharing subsidies have led to higher price hikes for Obamacare plans next year.
If conservatives can't change Obamacare's insurance rules, it could put the whole repeal-and-replace effort in jeopardy, Vox reports.
A look at 50 private companies set to reshape the business landscape.
A look at how leading portfolio managers and institutional investors build investment plans to meet clients’ goals.
Business icons and provocateurs share their innovative models. Learn how to upend old industries and start new ones that move markets.